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Abstract: Rizatriptan is a 5HT (IB/ID) agonist with proven efficacy in the acute treatment 
of migraine headache. We performed a systematic review of the literature for clinical trials 
of rizatriptan incorporating important patient outcomes including consistency of response, 
preference, satisfaction, and quality of life. We found evidence that rizatriptan provides 
consistent relief of migraine attacks and that patients prefer rizatriptan over other treatments 
because of its speed of relief. Patient satisfaction with rizatriptan is significantly higher than 
placebo, but appears equivalent to most other triptans. Migraine-specific quality of life at 
24 hours is significantly better in patients treated with rizatriptan compared to placebo, while 
overall long-term quality of life is less affected. The published clinical trials included in this 
systematic review are subject to bias due to the open-label nature of preference trials and the 
doses chosen for comparison in head-to-head trials.
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Background
Rizatriptan is a 5HT (1B/1D) receptor agonist and one of seven triptans available 
for acute migraine headache treatment. Rizatriptan’s efficacy and tolerability have 
been demonstrated by multiple randomized placebo controlled studies. A systematic 
review and meta-analysis of the available triptans in 2001 looked at 53 double-blind, 
randomized, placebo-controlled trials and compared the various triptans.1 The authors 
found that all oral triptans were effective and well tolerated. Based on their meta-
analysis, 10 mg rizatriptan, 80 mg eletriptan, and 12.5 mg almotriptan provide the 
highest likelihood of consistent success.
In contrast to the traditional measures of efficacy and tolerability, a much smaller 
number of studies have looked at patient satisfaction or preference for rizatriptan and 
quality of life measures. In this systematic review, our goal is to review the literature 
on patient satisfaction and preference, consistency of response, as well as studies 
analyzing quality of life for rizatriptan.
Preference and satisfaction for a certain medication is based on multiple factors. 
These include speed and degree of pain relief, headache recurrence, adverse symptoms, 
ease of medication administration, functional disability, and consistency of effect. 
Therefore, the composite endpoint of patient preference unifies these factors into a 
single global measure incorporating efficacy and tolerability, and is meaningful to 
both patients and physicians. In addition, studies have shown that patient preference 
is a sensitive clinical trial endpoint.2Patient Preference and Adherence 2009:3 252
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Quality of life is also a very important measure for 
patients taking acute migraine medications. Many patients 
can become severely disabled with their migraines, render-
ing them unable to go to work, school, or even to do daily 
household duties. Standardized and validated quality of 
life measures are available for migraine and are crucial to 
consider in addition to traditional measures of efficacy and 
tolerability.
Methods
A systematic review of clinical trials of rizatriptan for the 
treatment of migraine headache was performed. For the 
identification of studies considered for this review, a search 
strategy was developed for Ovid MEDLINE (1950 to 
April 2009) and EMBASE (1980 to April 2009). A very 
broad search strategy was employed in order to maximize 
the chance of finding relevant trials. The MEsH heading 
“migraine disorders” was cross-referenced with the term 
“rizatriptan” as a keyword. We limited our search to articles 
written in English. Clinical trials were included in the review 
if they had outcome measures pertaining to patient prefer-
ence, patient satisfaction, consistency of response, or quality 
of life. Data on patient satisfaction was only assessed from 
double-blind randomized studies. We included both open and 
double-blind trials using patient preference, consistency of 
response and quality of life as outcomes. Titles and abstracts 
identified by the literature search were screened for eligibility 
by two independent reviewers (TP and FA). Papers that could 
not be excluded with certainty on the basis of the informa-
tion contained in the title or abstract were retrieved in full 
for screening by both authors. Data on patient satisfaction, 
preference, consistency, and quality of life were abstracted 
by one researcher.
The combined search strategies yielded 1,461 abstracts. 
After analysis of the abstracts, 64 full text articles were 
reviewed. Twenty-four trials met our inclusion criteria and 
were included in the review (see Figure 1 for study flow 
diagram).
Meta-analysis was performed by treatment comparison 
type (ie, placebo, other triptans) if more than one trial was 
performed. Odds ratios (OR) were calculated with 95% 
confidence intervals (CI). OR from multiple studies were 
tested for homogeneity using the chi-squared test and by 
calculating the I-squared statistic. If study estimates were 
homogenous, they were combined using a fixed-effects model. 
When studies with heterogeneous results were clinically 
similar, the study estimates were combined using a random-
effects model. Clinical heterogeneity was assessed by looking 
at trial and patient characteristics and outcome measures. 
Trials required similar inclusion and exclusion criteria, 
clinical populations, and common outcome measures in order 
to be combined statistically using meta-analysis. Clinically 
heterogeneous studies were not statistically combined. 
We used Review Manager 5 software (available from the 
Cochrane Collaboration) to perform meta-analysis.
Results
Consistency
Three studies have looked specifically at consistency of 
response for patients using rizatriptan for their acute migraine 
headaches. These studies were not combined using meta-
analysis due to clinical heterogeneity; the trials employed dif-
fering research protocols and outcome measures (see Table 1 
for summary of data). Dahlof and colleagues3 performed 
post-hoc analysis on data from a randomized double-blind, 
placebo-controlled trial, to determine “within-patient consis-
tency” of response to rizatriptan. Within-patient consistency 
describes the percentage of patients who have a response to 
medication in a certain proportion of their migraine attacks. 
Patients treated four attacks, with four groups receiving 
rizatriptan 10 mg for three of four attacks, and placebo for 
the other attack, in different sequences, and the final group 
receiving rizatriptan 10 mg for all four attacks. The primary 
outcome of this study was pain relief at two hours. In patients 
who treated three of four attacks with rizatriptan, 86% had 
pain relief in at least two of those three attacks. In those 
treating all four attacks with rizatriptan, 73% had pain relief 
in at least three of four attacks.
Block and colleagues4 looked at the consistency of effect 
with rizatriptan compared to the standard treatment for 
migraine. This multicenter study randomized 1,831 patients 
with more than 46,000 attacks to rizatriptan 5 mg, 10 mg, 
or standard care. The rizatriptan groups were single-blinded 
and the standard care group was unblinded. The majority of 
patients in the standard care group used sumatriptan, alone 
or with nonsteroidal anti-inflammatory drugs (NSAIDs) or 
acetaminophen. The primary outcome was pain relief at two 
hours. For the 10 mg dose of rizatriptan, a median of 90% 
of attacks were relieved, as compared to 80% for rizatriptan 
5 mg, and 70% for standard care (p  0.05). The percent-
age of attacks relieved was similar for patients who treated 
just a few attacks as compared to those treating dozens of 
attacks.
Göbel and colleagues5 looked at the efficacy and toler-
ability of rizatriptan 10 mg treating up to three attacks of 
migraine in an open-label study. They found no evidence Patient Preference and Adherence 2009:3 253
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Potentially relevant clinical trials identified and 
screened for retrieval (n = 1461) 
Clinical trials retrieved for more detailed evaluation 
(n = 64) 
Excluded (n = 1397) 
Reasons included: not a clinical trial, review
article, basic science report, case report 
Potentially appropriate clinical trials to be included 
in meta-analysis (n = 31) 
Clinical trials excluded (n = 33) 
Reasons: not a clinical trial (n = 6), no 
patient preference, consistency, satisfaction 
of quality of life outcomes assessed (n = 27) 
Patient preference 
data (n = 10)  
Meta-analysis not 
possible; data 
individually
summarized  
Consistency 
data (n = 3) 
Meta-analysis 
not possible; 
data individually 
summarized  
Patient
satisfaction data 
(n = 14) 
Clinical trials included in 
meta-analysis (n = 6) 
and individually 
summarized (n = 1) 
Clinical trials excluded (n = 7) 
Reasons: open label (n = 2), 
retrospective comparison (n = 2), 
not a trial (n = 2), review article 
(n = 1) 
Quality of life 
data (n = 5)  
Meta-analysis 
not possible; 
data individually 
summarized  
Figure 1 Flow diagram of the selection of clinical trials and studies.
of tolerance to repeated use and headache relief was noted 
in 79% of attacks.
Preference
Ten open-label studies have looked at patient preference 
for rizatriptan versus other triptans and nontriptan medica-
tions (see Table 2 for summary of study data). These studies 
generally involve a cross-over design, in which the patient is 
instructed to treat two moderate to severe migraine attacks; 
one with rizatriptan and the other with another medication. 
At the final visit, patients are asked to complete a validated 
“Preference Questionnaire”. In these, the patient is asked 
which of the two medications they prefer, or if they have no 
preference. In those expressing a preference, they are then Patient Preference and Adherence 2009:3 254
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asked to choose the most important reason. Reasons include 
relieving headache faster, returning to normal activities more 
quickly, fewer side effects, ease of taking the medication, 
headache recurrence with other treatment, and faster relief of 
nausea, photophobia, and/or phonophobia. Meta-analysis of 
these studies was not possible due to clinical heterogeneity.
Láinez and colleagues6 compared the rizatriptan 10 mg 
wafer to eletriptan 40 mg tablets. Of 372 patients, 342 patients 
(92%) expressed a preference. Of these, 61% preferred the 
rizatriptan 10 mg wafer over eletriptan (p  0.001). The 
most common reason given for the preference was speed of 
headache relief.
Loder and colleagues7 compared rizatriptan 10 mg with 
sumatriptan 50 mg tablets. Of 472 patients, 374 expressed 
a preference. Of these, 213 (57%) preferred rizatriptan and 
the remainder (43%) preferred sumatriptan (p = 0.009). 
The most important reason for preference was faster pain 
relief. Pascual8 also did a similar study with these two 
medications. Of 425 patients, 44 patients (10.4%) did not 
express a preference. Of the 381 patients who did express a 
preference, 245 (64.3%) preferred rizatriptan and 136 patients 
(35.7%) preferred sumatriptan (p  0.001). Faster relief of 
headache was again the most important reason.
Iglesias and colleagues9 compared rizatriptan 10 mg 
with almotriptan 12.5 mg. Of 267 patients, 209 recorded a 
preference, with 114 (54.5%) preferring almotriptan, and 
95 (45.5%) preferring rizatriptan (p = 0.1663). The results 
in this case were not statistically significant. Faster headache 
relief was again the most important reason for preference.
An open-label study by Ng-Mak and colleagues10 
compared rizatriptan with patients’ usual care oral triptans. 
These included sumatriptan (49.6%), zolmitriptan (15.2%), 
Table 1 Summary of studies looking at consistency of effect for rizatriptan
Study Sample size Comparison Outcome measures Results
Dahlof, 20003 250 rizatriptan 10 mg in three of four 
attacks, or rizatriptan 10 mg in all 
four attacks
Pain relief at two hours Three of four attacks: 86% pain relief 
at two hours in at least two of three 
attacks.   All four attacks: 73% pain relief 
in at least three of four attacks
Block, 19984 1,831 rizatriptan 10 mg, 5 mg or standard 
treatment
Pain relief at two hours 90% for 10 mg, 80% for 5 mg, 70% for 
standard treatment
Göbel, 20015  25,501  Tolerance to rizatriptan use in up to 
three attacks
Tolerance, headache relief  No tolerance with repeated use 79% 
had headache relief within one hour
Table 2 Summary of studies looking at preference for rizatriptan versus other medications
Study Sample size Comparison Outcome Results
Láinez, 20066 372 rizatriptan 10 mg or eletriptan 
40 mg
Preference for one treatment 61% preferred rizatriptan
Loder, 20017 472 rizatriptan 10 mg or 
sumatriptan 50 mg
Preference for one treatment 57% preferred rizatriptan
Pascual, 20018 425 rizatriptan 10 mg or 
sumatriptan 50 mg
Preference for one treatment 10% had no preference 64% preferred 
rizatriptan
Díez, 20079 267 rizatriptan 10 mg or 
almotriptan 12.5 mg
Preference for one treatment 54.5% preferred almotriptan
Ng-Mak, 200710 673 rizatriptan 10 mg or usual care 
triptans
Preference for one treatment 19.6% no preference, 46.6% preferred 
rizatriptan, 33.7% preferred another 
triptan
Adelman, 200011 367 rizatriptan tablet vs wafer Preference for one treatment No preference found
Christie, 200312 439 rizatriptan 10 mg or ergotamine 
1 mg/caffeine 100 mg
Preference for one treatment 89% expressed preference. Of these, 
69.9% preferred rizatriptan
Pascual, 200513 1,353 rizatriptan 10 mg or usual 
nontriptan therapy
Preference for one treatment 78.8% preferred rizatriptan
Bell, 200614 1,489 rizatriptan 10 mg or usual care 
meds
Preference for one treatment 19.6% had no preference. 58% preferred 
rizatriptan
Láinez, 200515 259 rizatriptan 10 mg or usual meds Preference for one treatment 89% preferred rizatriptanPatient Preference and Adherence 2009:3 255
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eletriptan (13.8%), almotriptan (11.7%), frovatriptan (5.1%) 
and naratriptan (4.6%). Regarding medication preference, 
46.6% preferred rizatriptan, 33.7% preferred another oral 
triptan, and 19.6% expressed no preference.
The rizatriptan tablet and wafer have also been compared.11 
Of 367 patients, no preference was found for the tablet versus 
the wafer.
Rizatriptan 10 mg tablet was compared with two ergota-
mine 1 mg/caffeine 100 mg tablets in a study of  439 patients.12. 
89.1% of patients expressed a preference. Of these, 69.9% 
preferred rizatriptan (p  0.001). Faster relief of headache 
was the most important reason.
Another similar study13 looked at rizatriptan 10 mg 
wafer versus patients’ usual nontriptan therapy. Usual 
nontriptan medications included NSAIDs (57%), simple 
analgesics (27%), or ergot derivatives (16%). 78.8% of 
patients preferred rizatriptan (p  0.001). The most common 
reasons cited for preference were faster relief of headache 
and faster return to normal function. A similar study by 
Bell and colleagues14 compared rizatriptan 10 mg tabs with 
usual-care medications. These medications included sumat-
riptan (48.9%), zolmitriptan (15.8%), eletriptan (12.9%), 
almotriptan (12.0%), NSAIDs (5.4%), butalbital-containing 
combinations (4.3%) and isometheptene (3.4%). In terms 
of preference, 19.6% did not express a preference. Of the 
1,147 patients who did express a preference, 58% preferred 
rizatriptan (p  0.001).
A different type of study by Láinez and colleagues15 looked 
at productivity and quality of life, as well as preference for 
rizatriptan over usual medications. This was a prospective, 
open-label study at 27 work sites in Spain. Patients completed 
study questionnaires to assess quality of life: ML-96, and the 
Short Form Health Survey (SF-36) at baseline and then three 
months later. The ML-96 questionnaire has two parts. The first 
part evaluates the use of medical resources, and the second part 
assesses the effect of migraine on work loss and productivity. 
The SF-36 questionnaire is a validated tool designed to 
measure general health-related quality of life. Questions look 
at three aspects of health: functional status, well-being, and 
perception of health. 259 patients completed the study. Only 
7% had taken triptans in the past. Patients were instructed 
to treat moderate to severe migraines with rizatriptan 10 mg 
tabs, for the three-month duration of the study. After three 
months of rizatriptan therapy, the use of medical services was 
much lower, absenteeism from work was lower, and quality 
of life had improved (p  0.001). 89% preferred rizatriptan 
over their usual medications. Again, the most common reason 
for preference was rapid speed of headache relief.
Patient satisfaction
Patient satisfaction with therapy at two hours post-treatment 
was evaluated as a secondary outcome in six double-blind, 
randomized trials of rizatriptan versus placebo.16–21 Patients 
rated their satisfaction with the study treatment on a seven-
point scale, with 1 = completely satisfied, couldn’t be 
better; 2 = very satisfied; 3 = somewhat satisfied; 4 = neither 
satisfied nor dissatisfied; 5 = somewhat dissatisfied; 6 = very 
dissatisfied; 7 = completely dissatisfied, couldn’t be worse. 
Combination of data from the six trials using meta-analysis 
was performed (see Figure 2). The odds of being completely, 
very or somewhat satisfied using rizatriptan versus placebo 
was 4.62 (95% CI: 3.36, 6.36; p   0.00001).
Patient satisfaction with rizatriptan versus another triptan 
(sumatriptan, naratriptan, zolmitriptan) at two hours was 
Study or subgroup
Bomhof, 199917
Freitag, 200818
Goldstein, 199816
Kramer, 199819
Pascual, 200020
Tfelt Hansen, 199821
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.10; Chi² = 15.87, df = 5 (P = 0.007); I² = 69%
Test for overall effect: Z = 9.40 (P < 0.00001)
Events
108
117
695
224
183
224
1551
Total
192
185
1112
324
292
380
2485
Events
16
40
119
17
34
44
270
Total
101
92
428
83
146
156
1006
Weight
13.3%
15.5%
22.3%
13.8%
16.9%
18.1%
100.0%
M-H, Random, 95% CI
6.83 [3.73, 12.51]
2.24 [1.34, 3.72]
4.33 [3.39, 5.52]
8.70 [4.86, 15.58]
5.53 [3.52, 8.68]
3.66 [2.44, 5.48]
4.62 [3.36, 6.36]
Rizatriptan Placebo Odds ratio Odds ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favors placebo Favors rizatriptan
Figure 2 Patient satisfaction; rizatriptan versus placebo.Patient Preference and Adherence 2009:3 256
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evaluated as a secondary outcome in four double-blind, 
randomized trials.16,17,20,21 Meta-analysis of the data from 
the four trials was performed (see Figure 3). Patients taking 
rizatriptan were 1.32 times more likely to be completely, 
very or somewhat satisfied compared to those taking another 
triptan (95% CI: 1.09, 1.60; p = 0.005).
One trial compared patient satisfaction with rizatriptan 
10 mg versus ergotamine/caffeine in a double-blind crossover 
trial of 439 patients treating a single migraine attack with 
each therapy.12 Two hours after dosing, 69.8% of patients 
were completely, very or somewhat satisfied with rizatriptan, 
compared to 38.6% with ergotamine/caffeine (p  0.001).
Health-related quality of life
Five clinical trials of rizatriptan have assessed quality of life as 
a secondary outcome; four double-blind, randomized trials of 
rizatriptan versus placebo (and zolmitriptan in one trial), and 
one open-label extension trial of rizatriptan versus standard 
care. All studies used the 24-hour Migraine Quality of Life 
Questionnaire; the open-label trial also measured general 
health-related quality of life using the SF-36. The 24-hour 
Migraine Quality of Life Questionnaire is a validated instru-
ment, consisting of 15 questions divided into five domains: 
work functioning, social functioning, energy/vitality, migraine 
symptoms, and feelings/concerns. As the description of the 
study results was quite limited in three of the double-blind 
trials, and due to clinical heterogeneity of the remaining trials, 
the results were not combined using meta-analysis (see Table 
3 for summary of study data).
Santanello and colleagues22 reported the effects of riza-
triptan on migraine-specific quality of life in 247 patients 
participating in a substudy of a large randomized, double-
blind, placebo-controlled trial of rizatriptan 2.5 mg, 5 mg, 
10 mg, or placebo. Patients treated one moderate or severe 
migraine attack with study medication and completed the 
24-hour Migraine Quality of Life Questionnaire 24 hours 
after ingesting the test medication. The study found a signifi-
cant linear dose response for each of the domain scores in the 
24-hour Migraine Quality of Life Questionnaire. Statistically 
significant mean improvements were observed for patients 
treated with rizatriptan 10 mg compared with those treated 
with placebo in the social functioning, migraine symptoms, 
and feelings/concerns domains. Patients receiving rizatriptan 
10 mg experienced significantly better overall migraine-
specific quality of life compared to those on placebo.
Migraine-specific quality of life in patients using rizatriptan 
5 or 10 mg versus placebo was also briefly described in Teall’s 
study23 of 1473 patients, and Ahrens’ study24 of 634 patients. 
Teall reported that both doses of rizatriptan resulted in a 
significant improvement in quality of life scores in all domains 
over placebo, while Ahrens’ reported that the rizatriptan 10 mg 
wafer was statistically superior to the 5 mg dose in improving 
quality of life at 24 hours post-dose. Pascual’s study20 of 
rizatriptan 10 mg versus zolmitriptan 2.5 mg and placebo in 
776 patients reported that both rizatriptan and zolmitriptan 
were superior to placebo on all five quality of life domains and 
there were no differences between the active treatments.
Gerth and colleagues25 reported the effect of rizatriptan 
on migraine-specific quality of life at 24 hours and 
general health-related quality of life in a 12-month open-label 
extension trial of rizatriptan 10 mg versus standard care (which 
was sumatriptan for the majority of patients). 265 patients 
completed the 24-hour Migraine Quality of Life Question-
naire over the first month of the trial, and the SF-36 at baseline 
and at 2, 6, and 12 months. Patients randomized to rizatriptan 
10 mg had significantly better scores in all five domains 
of the 24-hour Migraine Quality of Life Questionnaire 
instrument. The magnitude of increase ranged from 11% in 
the work functioning domain to 26% in the feelings/concerns 
domain. With respect to general health-related quality of life, 
Study or subgroup
Bomhof, 199917
Goldstein, 199816
Pascual, 200020
Tfelt Hansen, 199821
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.02; Chi² = 5.57, df = 3 (P = 0.13); I² = 46%
Test for overall effect: Z = 2.83 (P = 0.005)
Events
108
695
175
224
1202
Total
192
1112
279
380
1963
Events
86
665
154
200
1105
Total
209
1114
282
380
1985
Weight
16.5%
38.4%
20.4%
24.7%
100.0%
M-H, Random, 95% CI
1.84 [1.24, 2.73]
1.13 [0.95, 1.33]
1.40 [1.00, 1.96]
1.29 [0.97, 1.72]
1.32 [1.09, 1.60]
Odds ratio Odds ratio   Other tirptan Rizatriptan
M-H, Random, 95% CI
0.2 0.5 1 2 5
Favors other triptan Favors rizatriptan
Figure 3 Patient satisfaction; rizatriptan versus other triptans.Patient Preference and Adherence 2009:3 257
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a significant improvement from baseline was only observed 
in the mental health domain of the SF-36.
Discussion
Rizatriptan is an effective therapy for acute migraine 
headaches, as demonstrated by multiple randomized double-
blind placebo-controlled studies. In reviewing the literature on 
consistency of effect, preference, satisfaction, and quality of 
life for rizatriptan, we can make the following conclusions.
Rizatriptan in most studies shows quite a good consistency 
of effect, in the range of 70% to 80% of attacks. There does 
not seem to be any tolerance or loss of efficacy with repeated 
use. Studies also indicate that rizatriptan is generally pre-
ferred over other triptans and nontriptan medications for acute 
migraine headaches. The majority of the studies on patient 
preference however were open-label and therefore unblinded. 
Although this is not uncommon in preference studies, biases 
may have entered these studies, from both the investigators 
and the patients. Most of the studies were financially spon-
sored by Merck Frosst, the maker of rizatriptan.3,4,6–8,10,12–15 
This bias likely resulted in the preference comparison of 
rizatriptan to the 50 mg dose of sumatriptan, rather than the 
100 mg dose, which may be more effective than the lower 
dose of sumatriptan in some patients.26 Furthermore, most 
studies compared only two attacks – one attack for each 
medication – which may not be enough time to determine 
whether a medication is effective and well tolerated.
The most important reason found for the preference of 
rizatriptan over other treatments was speed of headache relief. 
In clinical practice, it must be appreciated that each patient is 
unique, and that some patients respond to one triptan better 
than another triptan for reasons which are not understood. 
Given this fact, in many headache clinics, patients are given 
samples of two different triptans and asked to report back 
on which medication they felt was most effective for their 
migraine attack.
Patient satisfaction with rizatriptan is consistently higher 
than placebo, with convincing evidence of a greater than 
four-fold odds of satisfaction with rizatriptan over placebo. 
Greater patient satisfaction with rizatriptan than other triptans 
is less convincing. Only one of the four studies comparing 
patient satisfaction with rizatriptan to other triptans had a 
confidence interval that did not cross 1.0 (suggesting no 
difference between treatments), Bomhoff’s study of riza-
triptan versus naratriptan 2.5 mg. It is not surprising that 
rizatriptan was rated more satisfactory than its competitor in 
this study. Naratriptan has the slowest onset of action of all 
the triptans, with significant pain response rates at four hours 
rather than two hours.27 As speed of relief is highly valued by 
patients, it is more likely they will report greater satisfaction 
with a medication which has quicker onset to relief. Based 
on the summary of these results, there is no convincing 
evidence that patient satisfaction with rizatriptan exceeds 
that of other triptans, with the exception of naratriptan.
Migraine-specific quality of life at 24 hours appears 
reliably improved in patients using rizatriptan in comparison 
to placebo. Overall quality of life appears unaffected, with the 
exception of the mental health domain. Given that the SF-36 
Table 3 Summary of studies on rizatriptan and quality of life
Study Comparison Sample size Outcome studied Results
Santanello, 199722 Placebo, rizatriptan 
2.5 mg, 5 mg or 10 mg
n = 247 24 h MQoLQ Improvement in three of five domains 
of 24 h MQoLQ in rizatriptan 10 mg 
group compared to placebo: social 
functioning, migraine symptoms, and 
feelings/concerns
Teall, 199823 Placebo, rizatriptan 5 mg 
or 10 mg
n = 1473 24 h MQoLQ Improvement in all five domains of 
24 h MQoLQ in rizatriptan 5 mg and 
10 mg group compared to placebo
Ahrens, 199924 Placebo, rizatriptan 5 mg 
or 10 mg
n = 634 24 h MQoLQ rizatriptan 10 mg superior to 5 mg 
dose in improving quality of life
Pascual, 200020 Placebo, rizatriptan 10 mg, 
or zolmitriptan 2.5 mg
n = 776 24 h MQoLQ rizatriptan 10 mg and zolmitriptan 
2.5 mg superior to placebo in all five 
quality of life domains
Gerth, 200125 rizatriptan 10 mg or 
standard care
n = 265 24 h MQoLQ SF-36 rizatriptan 10 mg superior to standard 
care in all five domains of 24 h MQoLQ; 
significant improvement from baseline 
in mental health domain of SF-36
Abbreviations: 24 h MQoLQ, 24-hour Migraine Quality of Life Questionnaire; SF-36, Short Form Health Survey.Patient Preference and Adherence 2009:3
Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal that focusing on the growing importance of patient 
preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and 
their role in developing new therapeutic modalities and compounds to 
optimize clinical outcomes for existing disease states are major areas of 
interest. This journal has been accepted for indexing on PubMed Central. 
The manuscript management system is completely online and includes a 
very quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
258
Amoozegar and Pringsheim Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
is a generic health-related quality of life measure, it likely 
does not have the sensitivity to reliably detect small changes 
in overall function in patients with migraine. A quality of 
life measure which is more specific to patients with chronic 
pain would probably yield more impressive changes over 
time from effective migraine therapy. Certainly in clinical 
practice, when patients have effective, reliable acute therapy, 
they feel freer to perform activities, live more spontaneously 
and less in fear of their migraine attacks.
In conclusion, there is good evidence to support that 
rizatriptan is an effective, consistently successful treat-
ment for migraine headache that patients prefer over other 
therapies, and which patients feel satisfied with. Rizatriptan 
improves migraine-specific quality of life at 24 hours.
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